GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ACADIA Pharmaceuticals Inc (NAS:ACAD) » Definitions » Price-to-Free-Cash-Flow
中文

ACADIA Pharmaceuticals (ACADIA Pharmaceuticals) Price-to-Free-Cash-Flow

: 170.71 (As of Today)
View and export this data going back to 2004. Start your Free Trial

As of today (2024-04-24), ACADIA Pharmaceuticals's share price is $16.73. ACADIA Pharmaceuticals's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.10. Hence, ACADIA Pharmaceuticals's Price-to-Free-Cash-Flow Ratio for today is 170.71.

The historical rank and industry rank for ACADIA Pharmaceuticals's Price-to-Free-Cash-Flow or its related term are showing as below:

ACAD' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 169.57   Med: 245   Max: 309.49
Current: 170.78

During the past 13 years, ACADIA Pharmaceuticals's highest Price-to-Free-Cash-Flow Ratio was 309.49. The lowest was 169.57. And the median was 245.00.

ACAD's Price-to-Free-Cash-Flow is ranked worse than
86.32% of 212 companies
in the Biotechnology industry
Industry Median: 30.29 vs ACAD: 170.78

ACADIA Pharmaceuticals's Free Cash Flow per Share for the three months ended in Dec. 2023 was $0.52. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was $0.10.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was 46.10% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was 30.00% per year. During the past 10 years, the average Free Cash Flow per Share Growth Rate was 7.10% per year.

During the past 13 years, ACADIA Pharmaceuticals's highest 3-Year average Free Cash Flow per Share Growth Rate was 47.40% per year. The lowest was -70.70% per year. And the median was 8.50% per year.


ACADIA Pharmaceuticals Price-to-Free-Cash-Flow Historical Data

The historical data trend for ACADIA Pharmaceuticals's Price-to-Free-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ACADIA Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Free-Cash-Flow
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

ACADIA Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Price-to-Free-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison

For the Biotechnology subindustry, ACADIA Pharmaceuticals's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ACADIA Pharmaceuticals Price-to-Free-Cash-Flow Distribution

For the Biotechnology industry and Healthcare sector, ACADIA Pharmaceuticals's Price-to-Free-Cash-Flow distribution charts can be found below:

* The bar in red indicates where ACADIA Pharmaceuticals's Price-to-Free-Cash-Flow falls into.



ACADIA Pharmaceuticals Price-to-Free-Cash-Flow Calculation

ACADIA Pharmaceuticals's Price-to-Free-Cash-Flow ratio for today is calculated as

Price-to-Free-Cash-Flow Ratio=Share Price/ Free Cash Flow per Share (TTM)
=16.73/0.098
=170.71

ACADIA Pharmaceuticals's Share Price of today is $16.73.
ACADIA Pharmaceuticals's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.10.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Price-to-Free-Cash-Flow Ratio=Market Cap/Free Cash Flow

ACADIA Pharmaceuticals  (NAS:ACAD) Price-to-Free-Cash-Flow Explanation

Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.

In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.


Be Aware

In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.


ACADIA Pharmaceuticals Price-to-Free-Cash-Flow Related Terms

Thank you for viewing the detailed overview of ACADIA Pharmaceuticals's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


ACADIA Pharmaceuticals (ACADIA Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
12830 El Camino Real, Suite 400, San Diego, CA, USA, 92130
Acadia Pharmaceuticals Inc is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Executives
Austin D. Kim officer: EVP & General Counsel C/O ACADIA PHARMACEUTICALS INC., 12830 EL CAMINO REAL, SUITE 400, SAN DIEGO CA 92130
Brendan Teehan officer: EVP, COO, Head of Commercial C/O ACADIA PHARMACEUTICALS INC., 12830 EL CAMINO REAL, SUITE 400, SAN DIEGO CA 92130
Stephen Davis director, officer: PRESIDENT AND CEO ACADIA PHARMACEUTICALS INC., 12830 EL CAMINO REAL, SUITE 400, SAN DIEGO CA 92130
James Kihara officer: Principal Accounting Officer C/O ACADIA PHARMACEUTICALS INC., 12830 EL CAMINO REAL, SUITE 400, SAN DIEGO CA 92130
Mark C. Schneyer officer: Chief Financial Officer C/O ACADIA PHARMACEUTICALS INC., 12830 EL CAMINO REAL, SUITE 400, SAN DIEGO CA 92130
Laura Brege director C/O ONYX PHARMACEUTICALS, INC., 2100 POWELL STREET, EMERYVILLE CA 94608
Baker Bros. Advisors Lp 10 percent owner 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Douglas J Williamson officer: Executive VP, Research & Dev AVADEL PHARMACEUTICALS PLC, 10 EARLSFORT TERRACE, DUBLIN L2 D02 T390
Srdjan R. Stankovic officer: EVP C/O ACADIA PHARMACEUTICALS INC., 12830 EL CAMINO REAL, SUITE 400, SAN DIEGO CA 92130
Adora Ndu director C/O DBV TECHNOLOGIES S.A., 177-181 AVENUE PIERRE BROSSOLETTE, MONTROUGE I0 92120
Elena Ridloff officer: EVP and CFO C/O ACADIA PHARMACEUTICALS INC., 12830 EL CAMINO REAL, SUITE 400, SAN DIEGO CA 92130
Michael J. Yang officer: EVP AND CCO C/O ACADIA PHARMACEUTICALS INC., 12830 EL CAMINO REAL, SUITE 400, SAN DIEGO CA 92130
Elizabeth A. Garofalo director C/O ACADIA PHARMACEUTICALS INC., 12830 EL CAMINO REAL, SUITE 400, SAN DIEGO CA 92130
James M Daly director INCYTE CORPORATION EXPERIMENTAL STATION, RTE 141 & HENRY CLAY RD. BLDG E336, WILMINGTON DE 19880
Eric Alejandro Miller officer: Controller & PAO C/O ACADIA PHARMACEUTICALS INC., 3611 VALLEY CENTRE DRIVE, SUITE 300, SAN DIEGO CA 92130